聚桂醇在治疗下肢静脉曲张中初步临床应用

目的:探讨聚桂醇在治疗下肢大隐静脉曲张中的应用价值。方法:回顾性分析2013年9月-2015年9月医院确诊的下肢大隐静脉曲张患者75例(75条患肢)病例资料,根据治疗方案分为两组,33例(33条患肢)超声引导下注射聚桂醇泡沫硬化剂作为聚桂醇组,42例(42条患肢)行大隐静脉高位结扎+剥脱术作为手术组,记录手术时间、术中出血量、下床活动时间、住院时间、治疗费用及术后并发症发生率,门诊随访术后6、12个月,记录复发率。结果:聚桂醇组手术时间、下床活动时间均短于手术组,术中出血量、住院费用少于手术组,差异有统计学意义(P0.05);聚桂醇组皮下血肿、皮肤麻木感发生率明显低于手术组,差异有统计学意义(P0.05);聚桂醇组12个月复发率为12.12%低于手术组的33.33%,差异有统计学意义(P0.05)。结论:聚桂醇泡沫硬化剂注射是治疗下肢大隐静脉曲张的可选疗法。

Preliminary Application of Lauromacrogol in the Treatment of Varicose Veins of Lower Limb

ABSTRACT Objective: To investigate the application value of lauromacrogol in the treatment of varicose veins of lower limb. Methods: The medical records of 75 patients (75 affected limbs) with varicosis of great saphenous vein of lower limbs confirmed between September 2013 and September 2015 were analyzed retrospectively. According to the treatment regimen, the patients were divided into two groups. Among them, 33 cases (33 limbs) treated by ultrasound guided injection of foam sclerosing agent lauromacrogol were in- cluded in the lauromacrogol group while 42 cases (42 limbs) treated by high ligation of great saphenous vein combined with stripping were included in the operation group. The operation time, intraoperative blood loss, off-bed time, treatment costs and incidence of post- operative complications were recorded. Patients were followed up for 6 to 12 months after operation, and the recurrence rate was recorded. Results: The operation time, off-bed and length of hospital stay of the lauromacrogol group were shorter than those of the operation group; the intraoperative blood loss and hospitalization expenses were less than those of the operation group (P<0.05); The incidence rates of subcutaneous hematoma and skin numbness in the lauromacrogol group were significantly lower than those in the operation group (P<0.05); The 12-month recurrence rate in the lauromacrogol group (12.12%) was lower than that in the operation group (33.33%) (P<0.05). Conclusion: Injection of foam sclerosing agent lauromacrogol is an alternative minimally invasive therapy for treating varicosis of great saphenous vein of lower limbs.